MedPath

A phase 2 clincial study to evaluate safety and efficacy of AMG 785 in Skeletally Mature Adults With a Fresh Unilateral Tibial Diaphyseal Fracture Status Post Definitive Fracture Fixation With an Intramedullary Nail

Phase 2
Completed
Conditions
Health Condition 1: null- Fracture HealingHealth Condition 2: M844- Pathological fracture, not elsewhere classified
Registration Number
CTRI/2009/091/001044
Lead Sponsor
Amgen Technology Pvt Ltd
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
400
Inclusion Criteria

Inclusion Criteria:

Skeletally mature adults, age 18 to 85 years with radiographically closed growth plates

Fresh unilateral closed or Gustilo type I or type II open tibial fracture

Definitive fracture fixation with reamed (closed and open fractures) or unreamed (open fractures only) intramedullary nailing

Exclusion Criteria

Exclusion Criteria:

Major polytrauma or significant axial trauma

Associated lower extremity fracture that will delay subjects ability to bear weight beyond the normal time expected for a tibial shaft fracture

Use of bone grafts at the time of fracture fixation

Pathological fracture or metabolic or bone disease

History of symptomatic spinal stenosis or facial nerve paralysis

Malignancy within the last 5 years

Evidence of the following (currently or within the past 5 years): elevated transaminases, significantly impaired renal function, current hyper- or hypocalcaemia

Use of agents affecting bone metabolism

Subject refuses to use appropriate methods of contraception

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Time to radiographic healing for the AMG 785 and placebo groupsTimepoint: [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]<br>
Secondary Outcome Measures
NameTimeMethod
- Physical functioning as measured by change from baseline in the SF-36 PFTimepoint: [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]<br>;-Adverse events, vital signs, laboratory data, ECG parameters, formation of anti-AMG 785 antibodies, change in lumbar spine bone mineral density, long-term effect on radiographic healing and callus size and qualityTimepoint: [ Time Frame: 104 weeks ] [ Designated as safety issue: Yes ]<br>;-Subject incidence of revision surgeryTimepoint: [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]<br>;-Time to clinical healing as determined by the ability to bear weight on the fractured limb and the absence of pain at the fracture siteTimepoint: [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]<br>
© Copyright 2025. All Rights Reserved by MedPath